TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by EAM Investors LLC

EAM Investors LLC decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 26.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 128,923 shares of the biopharmaceutical company's stock after selling 47,036 shares during the quarter. EAM Investors LLC owned about 0.08% of TG Therapeutics worth $3,881,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bleakley Financial Group LLC purchased a new position in TG Therapeutics during the fourth quarter worth about $245,000. Castellan Group purchased a new stake in TG Therapeutics in the fourth quarter valued at $8,539,000. Barclays PLC increased its position in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. lifted its position in TG Therapeutics by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock valued at $16,859,000 after buying an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter valued at about $241,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 0.2 %

NASDAQ:TGTX traded up $0.07 during trading hours on Monday, hitting $38.39. The company's stock had a trading volume of 1,357,951 shares, compared to its average volume of 3,097,886. The stock has a fifty day moving average of $36.34 and a 200-day moving average of $31.99. The stock has a market capitalization of $6.03 billion, a P/E ratio of -383.86 and a beta of 2.14. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

TGTX has been the subject of several research reports. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.